Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors StudyBenzinga • 03/12/21
Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB AgonistPRNewsWire • 03/12/21